Navigation Links
Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Date:11/5/2007

r 600-patient Phase 3 study will demonstrate PI-88's effect not only for those patients likely to recur within a relatively short period of time, but also for those whose chance of recurrence is delayed, as the Phase 3 study is designed to treat and follow patients for a longer period of time."

The double-blind placebo controlled Phase 3 study is designed to assess, as its primary endpoint, improvement in disease free survival (DFS), amongst approximately 600 patients in countries across North America, Europe and Asia, following surgery to remove liver cancer tumors. Half of the patients in this study will be administered PI-88 after surgical removal of tumors and the remaining patients will receive a placebo so that a direct statistical comparison between the placebo and PI-88 can be made.

A copy of this poster presentation can be found at http://www.progen-pharma.com.

(1) Each year, the American Association for the Study of Liver Diseases

brings together over 6,000 hepatologists and hepatology health

professionals from around the world for its annual meeting to meet

and exchange the latest liver disease research, and discuss treatment

outcomes.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In a Phase 2 trial in post- resection liver cancer, 160mg of PI-88 demonstrated a 25% improvement in the primary endpoint of disease-free rate at 48 weeks and 78% improvement in secondary endpoint of disease-free survival. These results, combined with positive feedback from the FDA, provi
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 EuroPharma, Inc. signs exclusive ... use of super absorbency BCM-95® curcumin and ... The exclusive distribution territory for these ... store channel and professional channel, which includes ... BCM-95® is a highly absorbable curcumin. ...
(Date:12/16/2009)... RealMed has been ranked the ... 2009 Top 20 Best in KLAS ... RealMed is a dynamic revenue cycle management ... between healthcare providers and all ... specializing in vendor performance measurement in the ...
(Date:12/16/2009)... 16 Siemens Healthcare today ... to help healthcare ... deadlines defined within the HITECH provision of ... Featuring zero-percent interest terms for ... defer up-front payments associated with their technology ...
Breaking Medicine Technology:EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4Medication Telemonitoring Improves Compliance and Behavior in NIH Study 14209 1Medication Telemonitoring Improves Compliance and Behavior in NIH Study 14209 2SC Johnson a Best Company for Working Moms 57985 1SC Johnson a Best Company for Working Moms 57985 2SC Johnson a Best Company for Working Moms 57985 3Video 3A Anthem Blue Cross and the California Governors Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 57982 1Video 3A Anthem Blue Cross and the California Governors Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 57982 2Video 3A Anthem Blue Cross and the California Governors Council on Physical Fitness and Sports Launch the Live Like a Champion Tour 57982 3
... 2007 /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced the publication ... (Anticoagulation with rNAPc2,To Help Eliminate MACE)/TIMI 32 clinical ... Journal of of Cardiology (JACC), demonstrating,that higher-dose (greater ... protein c2 (rNAPc2) reduced the incidence,and duration of ...
... MILAN, Italy, June 15 /CNW/ - Today AMADEO, one ... of two,angiotensin receptor blockers in hypertensive patients with,diabetic ... Milan. The results from this study show that ,telmisartan ... , ,Commenting on ...
Other Medicine Technology:Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 2Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 3Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5
(Date:12/16/2009)... an advance that could help ease health and environmental ... development of technology for changing the behavior of nanoparticles ... into the environment. Their study was published in ACS, ... Jarvie from the UK Centre for Ecology and Hydrology ... the production of nanoparticles particles less than 1/1000th ...
(Date:12/16/2009)... Encourage Access to Quality, Cost-Effective Care , ... Washington, ... have debated the best ways to rein in runaway costs while ... An important part of the ongoing discussion includes how to ensure ... besides doctors of medicine (MDs) or osteopathy (DOs). In both ...
(Date:12/16/2009)... found very effective in the alleviation of symptoms associated with ... and a wide array of skin conditions. Currently over ... including over 50 branded BioVeda Health and Wellness Centers. ... ... 2009 -- BioVeda Health and Wellness Centers, LLC. is pleased ...
(Date:12/16/2009)... at all-time low, government report shows, , , WEDNESDAY, Dec. ... United States has reached almost 78 years, a record ... in 2007, women can expect to live to 80.4 ... to the report from the U.S. Centers for Disease ... can expect to live longer than their parents, life ...
(Date:12/16/2009)... new software program developed by CareRise will reduce the ... their staffing needs as it relates to the patient ... facilities to calculate their mandatory nurse-to-patient staffing needs, comply ... daily report as to how it affects their bottom ... management in the healthcare industry, has been allowed a ...
Breaking Medicine News(10 mins):Health News:Behavior modification could ease concerns about nanoparticles 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2
... been a spur to him making the most of his life ... it was probably one of the best things that has happened ... year in remission from the disease, when he will be signed ... now on he will have no regular medical checks that might ...
... the world-leading publisher of scientific, technical and medical information ... series of 2-volume titles designed to fill an important ... series has been developed to meet radiologists, need for ... readable format to make that information easy to locate ...
... Syneron(TM) Medical,Ltd. (Nasdaq: ELOS ), an ... elos(TM) combined-energy medical aesthetic devices, today announces ... Contouring Centers,for its LipoLite(TM) laser-assisted lipolysis device, ... Sono Bello Contouring Centers provide both ...
... June 10 Examination Management,Services, Inc. (EMSI), ... the nation, and Cybersettle, the world leader ... Cybersettle users with integrated,medical record retrieval services ... Combining Cybersettle,s Web-based dispute resolution system ...
... and beyond, PURCHASE, N.Y., June 10 ... and marketer of nutritional supplements that,help consumers manage ... address chronic joint pain, today announced plans to,augment ... response market,by launching Iceland Health(R) Advanced Memory Formula ...
... Headway, LLC (Medical Headway),is pleased to announce ... MedicalHeadway.com, dedicated to arming the public with ... of medicine. The company offers,consumers free and ... cutting-edge,professional medical treatment and product information., ...
Other Medicine News:Health News:'Cancer was one of the best things to happen to me... but I worry about the future' 2Health News:New 'Expert Radiology' series fills a gap among available clinical imaging references 2Health News:Syneron Signs Multi-Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite(TM) and VelaShape(TM) 2Health News:Syneron Signs Multi-Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite(TM) and VelaShape(TM) 3Health News:EMSI and Cybersettle Partner to Provide Cybersettle Clients With Medical Record Retrieval Services 2Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 2Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 3Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 4Health News:Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel 5Health News:A New Home for Medical Breakthroughs 2
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Anti-Rotavirus Antigen Assay (ELISA)....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
... Acolytes core technology relates to the ... enzyme found in all living cells. ... measured using bioluminescence. By coupling ... example via extraction using antibody-coated beads, Acolyte ...
Medicine Products: